Randomized phase III study of pegylated liposomal doxorubicin
plus bortezomib compared with bortezomib alone in relapsed or
refractory multiple myeloma: combination therapy improves time
to progression.

J 2007

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

ORLOWSKI, RZ., A. NAGLER, P. SONNEVELD, J. BLADÉ, Roman HÁJEK et. al.

Basic information

Original name

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Name in Czech

Randomizovaná studie fáze II porovnání kombinované léčby doxorubicin/bortezomib se samotným bortezomibem

Authors

ORLOWSKI, RZ. (840 United States of America), A. NAGLER (840 United States of America), P. SONNEVELD (840 United States of America), J. BLADÉ (840 United States of America) and Roman HÁJEK (203 Czech Republic, guarantor)

Edition

Journal of clinical oncology, United States, American Society of Clinical Oncology, 2007, 0732-183X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 15.484

RIV identification code

RIV/00216224:14110/07:00035887

Organization unit

Faculty of Medicine

UT WoS

000249416000018

Keywords (in Czech)

mnohočetný myelom;bortezomib;doxorubicin

Keywords in English

multiple myeloma; bortezomib;doxorubicin

Abstract

ORIG CZ

V originále

This phase III international study compared the efficacy and safety of a combination of pegylated liposomal doxorubicin (PLD) plus bortezomib with bortezomib monotherapy in patients with relapsed or refractory multiple myeloma. PLD with bortezomib is superior to bortezomib monotherapy for the treatment of patients with relapsed or refractory multiple myeloma. The combination therapy is associated with a higher incidence of grade 3/4 myelosuppression, constitutional symptoms, and GI and dermatologic toxicities.

In Czech

V publikaci jsou posány výsledky III fáze mezinárodní studie, ve které byly porovnávány účinky samotného bortezomibu a kombinované léčby s doxorubicinem.

Citovat

ORLOWSKI, RZ., A. NAGLER, P. SONNEVELD, J. BLADÉ and Roman HÁJEK. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. Journal of clinical oncology. United States: American Society of Clinical Oncology, 2007, vol. 25, No 25, p. 3892-3901. ISSN 0732-183X.

@article{837837,
   author = {Orlowski, RZ. and Nagler, A. and Sonneveld, P. and Bladé, J. and Hájek, Roman},
   article_location = {United States},
   article_number = {25},
   keywords = {multiple myeloma; bortezomib;doxorubicin},
   language = {eng},
   issn = {0732-183X},
   journal = {Journal of clinical oncology},
   title = {Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.},
   volume = {25},
   year = {2007}
}

TY  - JOUR
ID  - 837837
AU  - Orlowski, RZ. - Nagler, A. - Sonneveld, P. - Bladé, J. - Hájek, Roman
PY  - 2007
TI  - Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
JF  - Journal of clinical oncology
VL  - 25
IS  - 25
SP  - 3892-3901
EP  - 3892-3901
PB  - American Society of Clinical Oncology
SN  - 0732183X
KW  - multiple myeloma
KW  - bortezomib;doxorubicin
N2  - This phase III international study compared the efficacy and safety of a combination of pegylated liposomal doxorubicin (PLD) plus bortezomib with bortezomib monotherapy in patients with relapsed or refractory multiple myeloma. PLD with bortezomib is superior to bortezomib monotherapy for the treatment of patients with relapsed or refractory multiple myeloma. The combination therapy is associated with a higher incidence of grade 3/4 myelosuppression, constitutional symptoms, and GI and dermatologic toxicities.
ER  -

ORLOWSKI, RZ., A. NAGLER, P. SONNEVELD, J. BLADÉ and Roman HÁJEK. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. \textit{Journal of clinical oncology}. United States: American Society of Clinical Oncology, 2007, vol.~25, No~25, p.~3892-3901. ISSN~0732-183X.

Detailed Information on Publication Record